Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1989 Jun;65(764):362–366. doi: 10.1136/pgmj.65.764.362

The effects of low dose intravenous 99-126 atrial natriuretic factor infusion in patients with chronic renal failure.

A S Woolf 1, M A Mansell 1, B I Hoffbrand 1, S L Cohen 1, P J Moult 1
PMCID: PMC2429348  PMID: 2532741

Abstract

The aim was to study the renal and hormonal effects of intravenous 99-126 atrial natriuretic factor (ANF) infusion in a mixed group of patients who had moderate to severe chronic renal failure (CRF) and who were not treated with dialysis. The peak mean plasma level of ANF achieved during the experiment was at the upper limit of an absolute range of basal values previously recorded in a larger group of patients with similar degrees of renal impairment. A significant tissue effect was confirmed by rises in plasma and urinary cyclic guanosine monophosphate, the 'second-messenger' of ANF. ANF infusion increased sodium excretion rate by a mean of 68% compared with a fall of 40% in a placebo group, and significant increases in urinary albumin excretion occurred during the peptide infusion. Thus, the high levels of plasma ANF found in CRF may have a role in the maintenance of sodium balance. In addition, the proteinuric effect may be detrimental to long-term renal function.

Full text

PDF
362

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvestrand A., Gutierrez A., Bucht H., Bergström J. Reduction of blood pressure retards the progression of chronic renal failure in man. Nephrol Dial Transplant. 1988;3(5):624–631. doi: 10.1093/oxfordjournals.ndt.a091717. [DOI] [PubMed] [Google Scholar]
  2. Broadus A. E., Kaminsky N. I., Hardman J. G., Sutherland E. W., Liddle G. W. Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in man. J Clin Invest. 1970 Dec;49(12):2222–2236. doi: 10.1172/JCI106441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cole B. R., Kuhnline M. A., Needleman P. Atriopeptin III. A potent natriuretic, diuretic, and hypotensive agent in rats with chronic renal failure. J Clin Invest. 1985 Dec;76(6):2413–2415. doi: 10.1172/JCI112254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Couser W. G., Stilmant M. M. Mesangial lesions and focal glomerular sclerosis in the aging rat. Lab Invest. 1975 Nov;33(5):491–501. [PubMed] [Google Scholar]
  5. Fine L. G., Bourgoignie J. J., Hwang K. H., Bricker N. S. On the influence of the natriuretic factor from patients with chronic uremia on the bioelectric properties and sodium transport of the isolated mammalian collecting tubule. J Clin Invest. 1976 Sep;58(3):590–597. doi: 10.1172/JCI108505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gerzer R., Weil J., Strom T., Müller T. Mechanisms of action of atrial natriuretic factor: clinical consequences. Klin Wochenschr. 1986;64 (Suppl 6):21–26. [PubMed] [Google Scholar]
  7. Hasegawa K., Matsushita Y., Inoue T., Morii H., Ishibashi M., Yamaji T. Plasma levels of atrial natriuretic peptide in patients with chronic renal failure. J Clin Endocrinol Metab. 1986 Oct;63(4):819–822. doi: 10.1210/jcem-63-4-819. [DOI] [PubMed] [Google Scholar]
  8. Hillier P., Knapp M. S., Cove-Smith R. Circadian variations in urine excretion in chronic renal failure. Q J Med. 1980 Autumn;49(196):461–478. [PubMed] [Google Scholar]
  9. Itoh H., Nakao K., Mukoyama M., Shiono S., Morii N., Sugawara A., Yamada T., Saito Y., Arai H., Hosoda K. Effects of intravenously administered beta-human atrial natriuretic polypeptide in humans. Hypertension. 1988 Jun;11(6 Pt 2):697–702. doi: 10.1161/01.hyp.11.6.697. [DOI] [PubMed] [Google Scholar]
  10. Itoh H., Nakao K., Sugawara A., Saito Y., Mukoyama M., Morii N., Yamada T., Shiono S., Arai H., Hosoda K. Gamma-atrial natriuretic polypeptide (gamma ANP)-derived peptides in human plasma: cosecretion of N-terminal gamma ANP fragment and alpha ANP. J Clin Endocrinol Metab. 1988 Sep;67(3):429–437. doi: 10.1210/jcem-67-3-429. [DOI] [PubMed] [Google Scholar]
  11. Jones J. C., Carter G. D., MacGregor G. A. Interference by polar metabolites in a direct radioimmunoassay for plasma aldosterone. Ann Clin Biochem. 1981 Jan;18(Pt 1):54–59. doi: 10.1177/000456328101800111. [DOI] [PubMed] [Google Scholar]
  12. Meyer T. W., Anderson S., Rennke H. G., Brenner B. M. Reversing glomerular hypertension stabilizes established glomerular injury in renal ablation. J Hypertens Suppl. 1986 Dec;4(5):S239–S241. [PubMed] [Google Scholar]
  13. Richards A. M., Tonolo G., Montorsi P., Finlayson J., Fraser R., Inglis G., Towrie A., Morton J. J. Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man. J Clin Endocrinol Metab. 1988 Mar;66(3):465–472. doi: 10.1210/jcem-66-3-465. [DOI] [PubMed] [Google Scholar]
  14. Sagnella G. A., Markandu N. D., Shore A. C., MacGregor G. A. Effects of changes in dietary sodium intake and saline infusion on immunoreactive atrial natriuretic peptide in human plasma. Lancet. 1985 Nov 30;2(8466):1208–1211. doi: 10.1016/s0140-6736(85)90741-x. [DOI] [PubMed] [Google Scholar]
  15. Slatopolsky E., Elkan I. O., Weerts C., Bricker N. S. Studies on the characteristics of the control system governing sodium excretion in uremic man. J Clin Invest. 1968 Mar;47(3):521–530. doi: 10.1172/JCI105748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Smith S., Anderson S., Ballermann B. J., Brenner B. M. Role of atrial natriuretic peptide in adaptation of sodium excretion with reduced renal mass. J Clin Invest. 1986 Apr;77(4):1395–1398. doi: 10.1172/JCI112447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tarazi R. C., Dustan H. P., Frohlich E. D., Gifford R. W., Jr, Hoffman G. C. Plasma volume and chronic hypertension. Relationship to arterial pressure levels in different hypertensive diseases. Arch Intern Med. 1970 May;125(5):835–842. doi: 10.1001/archinte.125.5.835. [DOI] [PubMed] [Google Scholar]
  18. Woolf A. S., Moult P. J. Plasma levels of atrial natriuretic peptide in hyperthyroidism. Clin Endocrinol (Oxf) 1987 Dec;27(6):721–725. doi: 10.1111/j.1365-2265.1987.tb02956.x. [DOI] [PubMed] [Google Scholar]
  19. Zietse R., Schalekamp M. A. Effect of synthetic human atrial natriuretic peptide (102-126) in nephrotic syndrome. Kidney Int. 1988 Nov;34(5):717–724. doi: 10.1038/ki.1988.238. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES